Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
In a recent trial, dsm-firmenich’s solid CBD formulation showed comparable absorption results to a liquid oil-based reference product.
read more
Romvimza oral capsules will provide a new therapeutic option for a subset of patients with symptomatic tenosynovial giant cell tumor.
read more
The expansion of the Niederlenz facility will provide a dedicated space for customers to conduct trials and optimize their processes.
read more
Arcus announced that Gilead’s time-limited exclusive option rights to experimental oral small molecule, casdatifan, have expired.
read more
The San Diego-based biotech has raised $94.2 million to fund the development of its oral small molecule therapeutics for the treatment of metabolic diseases.
read more
Plant-based ingredients and excipients provider Roquette has launched a new and refreshed coatings platform for pharma and nutraceuticals.
read more
The San Francisco-based biotech has paused enrollment and dosing in a phase 2b trial of its lead candidate in patients with idiopathic pulmonary fibrosis.
read more
Axsome has resolved patent litigation related to Teva’s generic version of its top-selling tablet, Auvelity.
read more
Months after agreeing to pay $2.2 billion to resolve Zantac product liability cases, GSK faces a class action lawsuit from investors.
read more
Bangladesh-based conglomerate Advanced Chemical Industries plans to introduce a new subsidiary, ACI Herbal and Nutraceuticals.
read more
The Belgian CDMO will take ownership of the 50,000-square-foot CGMP facility in Somerset, New Jersey, and will add a new bioanalytical lab.
read more
The CDMO will manufacture clinical batches of Jotrol, Jupiter’s proprietary resveratrol-based therapeutic, using an optimized softgel formulation.
read more
Journavx tablets provide effective pain relief without the addictive potential of opioids.
read more
Pfizer will pony up close to $60 million to resolve Biohaven's bogus speaker program headache.
read more
Trial data shows potential for the treatment regimen to become the new standard of care for BRAF V600E-mutant metastatic colorectal cancer.
read more